Welcome to our dedicated page for CeriBell SEC filings (Ticker: CBLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode pages of FDA jargon and clinical-trial tables in CeriBell’s disclosures? Medical-device filings are notoriously dense, and CeriBell’s focus on AI-driven EEG technology only adds layers of regulatory nuance. Whether you’re hunting for cybersecurity risks tied to VA deployments or details on subscription revenue, finding answers quickly can feel impossible.
Our platform fixes that. Stock Titan’s AI reads every CeriBell annual report 10-K simplified, flags key FDA 510(k) milestones in each CeriBell quarterly earnings report 10-Q filing, and delivers plain-English takeaways you can act on. Need to monitor CeriBell insider trading Form 4 transactions? We stream CeriBell Form 4 insider transactions real-time, alerting you the moment an executive buys or sells. Material news breaks? A fresh 8-K appears and we publish CeriBell 8-K material events explained within minutes.
The result is clarity. Use our AI to compare R&D spend trends, track device-unit placements, or probe management incentives inside the next CeriBell proxy statement executive compensation. Dive into a concise CeriBell earnings report filing analysis or ask a natural question such as “understanding CeriBell SEC documents with AI” and get answers fast. From risk-factor red-flags to CeriBell executive stock transactions Form 4, every insight lives here—updated in real time and explained simply. No more endless scrolling through EDGAR; confident decisions start now.
Ceribell, Inc. (CBLL) reporting person Raymond Woo, Chief Technology Officer, disclosed an open-market sale of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the transaction he beneficially owned 147,704 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. No derivative transactions were reported.
Ceribell, Inc. (CBLL) director and President & CEO Jane (Xingjuan) Chao reported a sale of 2,887 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the sale, the filing shows Ms. Chao directly beneficially owns 773,135 shares. The report also discloses an indirect interest of 369,088 shares held by the ACP 2021 Trust, for which she is a co-trustee and from which she disclaims beneficial ownership except to the extent of her pecuniary interest.
The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing records a routine disposition of shares by an insider who holds substantial direct and indirect positions, and it includes the required explanatory note about the trustee relationship and disclaimer of beneficial ownership.
Ceribell, Inc. (CBLL) insider Scott Blumberg, who is Chief Financial Officer and a director, reported a disposition of 687 shares of common stock on 08/25/2025 at a price of $11.58 per share. After the reported sale, Mr. Blumberg beneficially owned 119,374 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025. The filing lists no derivative transactions or additional explanations.
Joseph M. Taylor, a director of Ceribell, Inc. (CBLL), reported the sale of 7,032 shares of Common Stock on 08/19/2025 at a weighted-average price of $11.76. After the reported disposition, the filing shows the reporting person beneficially owned 59,235 shares. The Form 4 was filed as a single reporting-person filing and was signed by an attorney-in-fact.
CeriBell, Inc. (CBLL) Form 144: This notice reports a proposed sale of 7,032 shares of common stock through Fidelity Brokerage Services on 08/19/2025 with an aggregate market value of $82,690.42 and 36,663,968 shares outstanding. The shares were acquired via restricted stock vesting from the issuer: 414 shares vested on 06/01/2025 and 6,618 shares vested on 06/10/2025, with payment characterized as compensation. The filer states there were no securities sold in the past three months for the account reported and affirms no undisclosed material adverse information is known.
Form 144 filing for CeriBell, Inc. (symbol: CBLL) discloses that an affiliate, Xingjuan Chao, plans to sell up to 25,000 common shares through Fidelity Brokerage Services. The proposed sale, valued at $470,000, represents roughly 0.07 % of the 36.14 million shares outstanding and is expected to occur on or about 07 July 2025 on the NASDAQ exchange.
The shares stem from an employee option granted on 07 July 2021 and exercised for cash on the same date as the planned sale. During the previous three months, the same seller executed six separate transactions totaling 75,000 shares and generating ≈ $1.23 million in gross proceeds.
No additional financial statements, earnings figures, or corporate actions are included in this filing. The document is limited to the proposed share sale details required under SEC Rule 144.
FAQ
What is the current stock price of CeriBell (CBLL)?
What is the market cap of CeriBell (CBLL)?
